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Abstract
Gonadotropins, including human chorionic gonadotropin (hCG), have been 
used since and for several decades to treat infertility by ovarian stimulation. hCG 
is the most important protein for embryogenesis and embryo development and 
implantation in uterus upon fertilization of oocytes. The hCG used for in-vitro 
fertilization (IVF) is being extracted from urine of pregnant women, and it does 
inevitably contains other proteins secreted into urine. The presence of other 
proteins varies from batch to batch, and it can be significantly high. Due to the fact 
that many of the proteins identified in these formulations can trigger an allergic 
reaction, which, in turn, can affect the embryogenesis and prevent embryo implan-
tation, it is very important to check the amount and type of contaminant proteins 
in pharmaceutical formulations. It was found that the total protein content varied 
from batch to batch, and a large number of contaminant urinary proteins were 
identified in all analyzed samples except for the recombinant product.
Keywords: embryogenesis, in-vitro fertilization, human chorionic gonadotropin, 
proteomics
1. Introduction
Human chorionic gonadotropin (hCG) is one of the most widely studied 
markers in embryonic development. It is used as an obstetric marker, and it is often 
regarded as little more than a signal for maternal recognition of pregnancy. Human 
chorionic gonadotropin is a member of the dimeric glycoprotein hormone family 
that also includes FSH, LH, and TSH. The members of this hormone family share 
a common α subunit and have a unique β subunit to each hormone. Additionally, 
each hormone shows a different level of glycosylation, which determines circulating 
half-life and receptor binding affinity [1].
The success of embryo implantation upon IVF and embryo transfer depends on 
various factors related to the embryo quality and patient’s endometrial receptivity. 
Upon implantation, it is important that the embryo reaches the endometrial cavity 
during the period of time in which the endometrium is receptive. It has been esti-
mated that 50–75% of lost pregnancies are due to the embryo’s implantation failure 
as described by Tsampalas et al. [2]. Many factors are involved in the implantation 
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process, which is very intricate process and the success can be influenced by many 
factors. The most important regulation of embryogenesis and embryo implantation 
in uterus is performed by hCG, and studies performed by Licht et al. [3] showed 
that an intrauterine injection of 500 IU of hCG/mL inhibited the expression of 
intrauterine insulin-like growth factor-binding protein 1 and the macrophage 
colony stimulating factor. It was also demonstrated that an intrauterine injection of 
500 IU of hCG performed before embryo transfer significantly improved both the 
implantation and pregnancy rates in IVF/intracytoplasmic sperm injection cycles.
The use of gonadotropin derived from either animal or human tissues was not 
always without clinical danger (e.g., antibody formation from pregnant mare serum 
gonadotropin and Creutzfeld-Jacob disease from human pituitary gonadotropin).
The hCG is being extracted from urine of pregnant women (uhCG) for almost 
three decades, and it is being used for induction of mid-cycle follicular matura-
tion and ovulation in women undergoing an IVF treatment. Originally, hCG 
in pharmacological preparations was derived only from the urine of pregnant 
women. However, due to their biological origin, these hCG products show large 
biological variability and significant batch-to-batch variation. Therefore, recom-
binant technology has been introduced for the production of recombinant hCG 
(rhCG) with higher purity and higher batch-to-batch reproducibility and the 
possibility to control their availability in different doses The availability of differ-
ent amounts of active substance in recombinant products provides a good starting 
point to develop personalized therapy for patients depending on their individual 
hormonal status.
Although a recombinant product is available on the market, urinary prepara-
tions of this hormone are still manufactured and are widely used [4–9]. Often, the 
urinary preparations are associated with problems arising from the fact that the 
starting material might origin from unknown sources, have poor purity, and lead to 
large batch-to-batch variations in activity and the amount of other proteins.
Analysis of commercially available, uhCG, was performed earlier [8], and 
discussions about the possible risks of infection were published [9–15].
We have analyzed several batches of both urinary derived and recombinant hCG 
formulations and have compared the obtained results in terms of number of identi-
fied proteins and their function during the embryogenesis.
2. Materials and methods
 2.1 Analyzed hCG: source of the material
Different batches of both uhCG and rhCG were purchased through the phar-
macy of the General Hospital of Vienna and by direct purchase from pharmacies in 
Bosnia-Herzegovina and Serbia. Details on manufacturer and batches analyzed are 
shown in Table 1.
 2.2 Proteomics sample preparation
Trypsin for protein digestion was purchased from Promega Inc. (Vienna, 
Austria). Solvents for HPLC—methanol (MeOH), acetonitrile (AcN), 2,2,2-tri-
fluoroethanol (TFE), formic acid (FA), heptafluorobutyric acid (HFBA), iodoacet-
amide (IAA), triethyl bicarbonate (TEAB), and dithiothreitol were purchased from 
Sigma-Aldrich (Vienna, Austria). Digestion of hCG and FSH was performed using 
the routine approach described in earlier publications [16].
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 2.3 Chromatographic separation and detection
All separations were performed using the nanoRSLC UltiMate 3000 HPLC sys-
tem coupled to the Q-Exactive Orbitrap Plus mass spectrometer (ThermoScientific, 
Vienna, Austria). Digested hCG and FSH were separated using trap column for sample 
loading and focusing (Acclaim PepMap C18, 300 μm ID × 5 mm, ThermoScientific, 
Vienna, Austria) and the pillar-arrayed-column (μPAC) with 2 μm interpillar distance 
and 2 m separation path (PharmaFluidics, Gent, Belgium) as the separation column. 
Both columns were operated in the column oven at 50°C. The sample was loaded onto 
the trap column using aqueous 0.01% HFBA at 30 μL/min and separated using the 
gradient generated by mixing mobile phases A (95% water, 5%AcN, and 0.1%FA) and 
B (50%AcN, 30%MeOH, 10% TFE, 10% water, and 0.1%FA).
Detection was performed using both UV at 214 nm and MS using positive 
electrospray ionization with a nanosource and ionization needle of 20 μm ID and 
10 μm tip. The 20 most intensive signals in each MS scan were selected for MS/MS 
(fragmentation) with HCD at normalized collision energy (NCE) set to 30.
 2.4 Data analysis
Raw data were transformed into Mascot generic files (MGF) for database search 
using MSConvert (www.proteowizzard.sourceforge.net). The database search 
was performed using the in-house Mascot server v.2.6 and the SwissProt database 
(status January 2018) using following parameters: trypsin was selected as enzyme, 
peptide mass precision was set to 10 ppm, carboxymethylation on Cys was selected 
as fixed modification and oxidation on Met, and phosphorylation on Ser, Thr, and 
Tyr were set as variable modifications.
Pathway analysis was performed using String (www.string-db.org).
Commercial name and 
charge number
Dosage Principal 
component
Origin Manufacturer
Pregnyl_M038101 5000 IU/mL hCG Urinary-
derived
MSD (N.V. 
organon, NL)
Pregnyl_M011526 5000 IU/mL hCG Urinary-
derived
MSD (N.V. 
organon, NL)
Pregnyl_354043 5000 IU/mL hCG Urinary-
derived
MSD (N.V. 
organon, NL)
Predalon_117730 5000 IU/mL hCG Urinary-
derived
MSD (N.V. 
organon, NL)
Pregnyl_117447 5000 IU/mL hCG Urinary-
derived
MSD (N.V. 
organon, NL)
Pregnyl_116935 1500 IU/mL hCG Urinary-
derived
MSD (N.V. 
organon, NL)
Pregnyl_M018720 5000 IU/mL hCG Urinary-
derived
MSD
Chorimon_160432 5000 IU/mL hCG Urinary-
derived
Institut 
Biochimique SA, 
CH
Ovitrelle 250 μg/0.5 mL hCG Recombinant Merck Serono 
(Feltham, 
Middlesex, UK)
Table 1. 
Analyzed products, batch numbers, and manufacturers’ names of analyzed samples.
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3. Results
 3.1 Identification of contaminant proteins in hCG preparations
All sample preparations were performed using standard procedures used in the 
Proteomics Core Facility of the Medical University of Vienna. No gel separations 
have been performed, and all results are generated upon the in-solution digest 
of different commercial formulations. Following chromatographic separation of 
tryptic peptides, the detection was performed using nanoelectrospray positive 
ionization and database search using the common SwissProt database.
For all analyzed samples, active substances were identified as major compounds. 
However, a number of other proteins were also identified in all samples. Figure 1 
shows an exemplary total ion chromatogram (TIC) of an hCG sample.
Table 2 shows the total number of identified compounds in each of the analyzed 
sample in addition to the main sample component, and an overview of the proteins 
with the highest scores identified in all samples is shown in Table 3.
 3.2 Contaminant proteins in rhCG preparations versus uhCG
Recombinant hCG was significantly cleaner but a certain number of other 
proteins were also identified. Although the majority of these proteins seem to be 
Sample’s commercial name Pregnyl Chorimon Ovitrelle
Number of analyzed batches 7 1 1
Origin Urine Urine Recombinant
Number of additionally identified proteins 383 21 9
Table 2. 
Total number of proteins identified in addition to the main therapeutic component in each of the samples’ groups.
Figure 1. 
Total ion chromatogram (TIC) of tryptic peptides generated from a Pregnyl formulation.
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common contaminants such as keratins, in order to ensure that these proteins do 
not origin from previous injections of urinary formulations, blank sample injections 
(buffer used for dissolving peptides) were analyzed before and after the injection of 
each sample, and the TIC of such a blank injection is shown in Figure 2.
4. Discussion
In European Union, the production and the quality of medical products for both 
human and animal use is strongly regulated and controlled from both national 
u-hCG u-hCG-HP r-hCG
Uromodulin
Ribonuclease pancreatic
Nonsecretory ribonuclease 
Apolipoprotein D
Protein AMBP
Prothrombin
Growth/differentiation factor 15
Insulin-like growth factor-binding 
protein 7
Cystatin-M
Prostaglandin-H2 D-isomerase
Growth/differentiation factor
Peptidoglycan recognition
Protein 1
Prostaglandin-H2 D-isomerase
Protein AMBP
Bone marrow proteoglycan complement 
component C7
Neutrophil gelatinase-associated
lipocalin
Serum albumin
Apolipoprotein D
Ribonuclease pancreatic
Serum albumin
Prelamin-A/C
Keratin, type I 
cytoskeletal 9
Keratin, type I 
cytoskeletal 10
Keratin, type I 
cytoskeletal 14
Histone H1.2
Jupiter microtubule 
associated
homolog 2
Nucleoside 
diphosphate
kinase A
Keratin, type II 
cytoskeletal 1
Trypsin-3
Table 3. 
Proteins identified with highest scores in analyzed samples.
Figure 2. 
Blank injection following analysis of digested recombinant hCG.
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Figure 3. 
Pathway describing the interdependence of hCG and LHB both of which were identified in recombinant 
products.
health agencies and qualified bodies and from the European Medicines Agency. 
Companies producing medicines and medical devices must follow strict and 
detailed guidelines and secure that all operations are performed under governing 
GMP and GLP rules. These precautions shall secure the quality of the product and 
the safe use for the patients. Thennati et al. has described the method for the qual-
ity control of the recombinant product is ensured through analytical steps using 
SDS-gel separation and MALDI-ToF analysis of the final product [17]. Therefore, it 
was a great surprise to identify a number of proteins originating from the starting 
product (urine) in different batches of the final product.
A discussion on contaminant proteins in hCG formulations has already been 
published [4, 5, 7, 17–19], and several publications address the possibility of the 
presence of harmful substances in commercial formulation [13–15, 20–22] but no 
final decision was made and the urinary-derived hCG formulations are still widely 
used although it has been shown that recombinant hCG can be used with the same 
success rate.
Due to the lack of published data and reports on hCG formulations and the lack 
of information about these products, we have analyzed commercially available 
formulations that are routinely prescribed for patients undergoing IVF treatment.
The major active component, hCG, was identified in all analyzed samples and, 
in addition, human serum albumin (HSA), luteotropin subunit beta (LSHB), and 
glycoprotein hormones alpha chain (CGA). The presence of HSA in all samples 
can be explained by its secretion in urine and by the need of growing CHO cells, 
for recombinant hCG production, in culturing medium supplemented with HSA, 
which might contain a number of other proteins that were not removed when HSA 
purification was performed. The pathway and interaction analysis, shown in Figure 3,  
explains the dependence of co-expression between the hCG, LHB, and CGA 
and explains why these proteins can also be identified in recombinant products. 
Obviously, the production of hCG also induces the expression of other proteins 
involved in ovarian steroidogenesis, hormone activity, and regulation of hormone 
levels, which are identified with high confidence with MS/MS analysis. However, 
in this case, the identification of LHB is a false positive one, and we cannot claim 
that this protein is really present in the recombinant sample. The reason is that hCG 
and LHB have a common amino acid sequence between amino acids on positons 22 
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and 131 in the protein backbone. If other parts of the sequence cannot be identified, 
we cannot tell the proteins apart. However, in this case, the identification score 
and the identification of other amino acids in the hCG sequence show an unique 
identification.
 4.1 Contaminant proteins in urinary-derived samples
As for the contaminants in urinary-derived products, uromodulin, which is 
also the major urinary protein, was a major hit following the major component. 
However, other proteins, such as alpha-1-microglobulin or apolipoprotein D, and 
prostaglandin were identified with high confidence. The contaminants in urinary-
derived hCG formulations resemble urinary proteins identified in urine-only 
samples, which were described in a recently published study on stress-induced 
urinary incontinence [23].
Keratin was one of the major alien contaminants, and its presence suggests a 
contamination during the sample production and the origin might be the insuf-
ficient air-conditioning or the contamination of the packaging units, which might 
be traced back to the use of latex-made gloves, dust containing skin particles, etc. 
We can exclude the contamination in our lab since all sample preparation steps have 
been performed using the laminar flow and using nitrile gloves. The blank samples 
show no identifications of keratin or of other contaminations.
Additional distinction between the urinary and the recombinant products can 
be seen when looking at the GO analysis of the biological processes where these 
proteins are involved, as shown in Figure 4.
 4.2 Contaminant proteins in recombinant samples
Products originating from the production process employing recombinant 
method have significantly less contaminant proteins of human origin. To our best 
knowledge, until now, there are no reports describing contaminations for recombi-
nant hCG. Upon analysis, the hCG was the major component identified with con-
taminants such as keratin and human serum albumin (HSA). These contaminants 
are easy to explain, we have given an explanation for keratin in previous section, 
and HSA is most probably a contaminant from the culturing medium of CHO that 
was not completely removed upon hCG extraction.
Figure 4. 
GO term analysis of proteins identified in both urinary and recombinant formulations showing differences in 
their abundancies in biological processes.
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 4.3 Embryogenesis and hCG, influence of contaminants
Often, hCG is also known as “the hormone of pregnancy”. It plays an important 
part for establishing and maintaining pregnancy, and it is extensively used in IVF 
procedures. A serial measurement of hCG every 48 hours is being used to confirm 
the early pregnancy and to distinguish between normally progressing pregnancies 
from ectopic pregnancies or spontaneous abortions [10]. It was shown that the 
miscarriage rate is higher when assisted reproductive techniques (ARTs) are applied 
than with naturally occurring pregnancy [11]. Girard et al. evaluated the associa-
tion between early β-hCG concentration increases, blastocyst morphology, and 
pregnancy evolution in a single-blastocyst transfer program. In most IVF laborato-
ries, blastocyst transfers are associated with higher success rates of implantation as 
compared with the cleavage stage embryo as shown by Oron et al. [12] and Girard 
et al. [10]. Most laboratories report that blastocysts are selected for transfer accord-
ing to their morphological characteristics. That means that physicians decide on 
implantation based on, that is, expansion degree, hatching status of the blastocysts, 
inner cell mass, or trophectoderm characteristics.
It is taught that hCG is involved in embryo implantation by modulating the activ-
ity of collagenases and plasminogen activators in an in-vitro system, as described by 
Yagel et al. [13]. Furthermore, it is an interesting and noteworthy feature that most 
of the mediators that have earlier been considered essential for the implantation pro-
cess (i.e., EGF and IL-1/IL-6) are also involved in the regulation of hCG biosynthesis 
by the placental syncytiotrophoblasts [13–15] probably by modulating trophoblast 
differentiation. Therefore, Licht et al. postulated that hCG may play a central part in 
the hypothetical embryo-maternal cross talk and tested the hypothesis by simulating 
the effect of a very early pregnancy on the decidualized endometrium. The results 
suggested that, no immunoreactive hCG was found in the peripheral circulation 
(hCG<5 mIU/mL) and the treatment did not alter progesterone secretion by the 
corpus luteum, thus suggesting that the effects observed were direct.
As described in previous paragraph, urinary-derived hCG contains high number 
of contaminant proteins. Considering that, particularly, EGF is present in high con-
centrations in almost all tested commercial preparations of urinary-derived hCG, 
and additional experiments are needed to find out whether the effects observed are 
due to hCG or to a contamination from the formulation.
Furthermore, contaminant proteins identified in hCG formulations can be 
the source of severe allergic reactions and can also trigger immune response that 
must not necessarily been manifested externally; however, it can negatively affect 
embryo implantation and embryogenesis. Koh et al. [16] and Phipps et.al [17] 
described the cases of IgE-mediated immunoreaction after intramuscular admin-
istration of urinary-derived gonadotropins. This type of allergic reactions occurs 
shortly after administration of urinary-derived gonadotropin, and it occurs with 
symptoms like shortness of breath, wheezing, flushing, general weakness, and diz-
ziness. In all reported cases, the IgE-mediated allergic reaction could be confirmed 
after intradermal skin testing with the same uhCG lot. Testing with rhCG triggered 
no reaction, thus confirming the theory that some urinary proteins can trigger an 
immune response and might be responsible for anaphylactic reactions. Immune 
reaction could also influence the development of the embryo and hinder normal 
embryogenesis and embryo implantation in endometrium.
Kajihara et al. [18] proposed that some urinary-derived hCG (uhCG) impurities 
like EDN or ribonuclease 2 could influence inflammatory and immunological processes 
through regulation of apoptosis in endometrial cells and, therefore, directly influence 
embryo nesting and development during IVF. Considering that some patients undergo 
lengthy and intensive treatment with uhCG, an effect cannot be excluded.
9© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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Uromodulin, as the most abundant protein in human urine, is also detected 
in various uhCG formulations as the most abundant one. Uromodulin has been 
described as a powerful stimulator of the immune system through its ability to 
bind on the surface of almost all blood cells and to encourage the cellular produc-
tion of cytokines, increase lymphocyte proliferation and phagocytosis [19, 20]. 
Using a mouse model, de Silva Antunes et al. suggested that uromodulin, but also 
some other urinary proteins, that is, major urinary proteins [13, 14, 17] or kidney 
androgen-regulated protein act as a possible allergens in the T-cell-mediated allergic 
reaction [21]. Otherwise, Phinuster et al. [22] suggested protective role of uro-
modulin in amniotic fluid in the fetus defense against anti-allogenic antibodies and 
immunosuppressive effect on T-cell-mediated allogenic rejection.
5. Conclusion
Formulations of hCG, both urinary and recombinant, contain contaminant 
proteins that originate from either starting material or has been introduced during 
the manufacturing process. The information about these contaminants cannot be 
identified on products’ leaflets.
We could show that urinary-derived products contain a significant number 
of human proteins that obviously originate from the starting raw material—the 
human urine.
We think that this issue must be approached and discussed since the recombi-
nant proteins show no such contamination and their use has been proven safe and 
effective.
Due to an important role played by hCG in embryo development in healthy sub-
jects and embryo implantation during the IVF procedure, it is of great importance 
to thoroughly check the quality of the formulations and apply production steps for 
the best possible removal of all contaminant proteins from the final product and 
prevent possible adverse and allergic reactions, which might affect embryogenesis 
in general and embryo implantation in uterus.
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